EUROFINS SCIENTIFIC : Eurofins signs definitive agreement to acquire majority stakes in Institut Pasteur de Lille subsidiaries, IPL SED Nord and IPL Invest.


03 October, 2011

Following the signing of an exclusive discussion agreement with the Fondation Institut Pasteur de Lille (IPL) on the 19th of July, 2011*, Eurofins Scientific announces that it has signed a definitive, mutually-binding agreement on the 30th of September to acquire a 67% stake in each of its two subsidiaries, namely IPL Invest and IPL Santé Environnement Durable Nord (IPL SED Nord). These entities are leaders in the French environmental testing market, and generate combined annual revenues of approximately EUR 45m.

The transaction to take a controlling stake in the aforementioned companies is expected to be completed on the 31st of October, 2011, and is subject to customary formal closing conditions. In preparation of the expected integration of the IPL SED companies into Eurofins, both groups have commenced a commercial and technical cooperation to combine their expertise in environmental analysis, and now offer customers an integrated portfolio of high-quality analytical solutions, with an optimal coverage of the French market.

*Communicated in a press release dated 20 July, 2011

For further information please contact:

Investor Relations and Corporate Communications

Phone:    +32-2-769 7383   


Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics and central laboratory services.

With about 9,500 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.

Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Activité de l'émetteur (acquisitions, cessions...) Communiqué intégral et original au format PDF : © Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur
Receive by email the next press releases of the company by registering on, it's free

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant